Patient Care and General Interest
ALERT!
This site is not optimized for Internet Explorer 8 (or older).
Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.
Lung Cancer - Chemotherapy
August 31, 2018
May 31, 2018
This randomized trial evaluating the relative efficacy of immunotherapy and chemotherapy in patients with recurrent or metastatic disease, immunotherapy was associated with significantly better progression-free survival. Tumor mutational burden was a marker for patient selection for immunotherapy.
May 30, 2018
The addition of pembrolizumab (targeting PD-1) to standard chemotherapy substantially improved time to progression and overall survival compared to chemotherapy alone in patients with metastatic lung cancer.
April 13, 2018
The authors found that adjuvent chemoradiotherapy after resection of N2 NSCLC was more effective if given sequentially than concomitantly.
March 30, 2018
Patient CareHigher risk of death from coronary artery disease was noted for Americans who drank higher quantities of sugary beverages but not for those who ate more sugary foods.
March 9, 2018
Patient Care
Carter Capps, a pitcher for professional baseball team the San Diego Padres, has made himself a necklace out of the rib surgeons removed during his thoracic outlet surgery.
October 24, 2017
A useful reminder of the substantial progress that has been made and the continuing challenges that we face in fighting this terrible disease.
August 2, 2017
This is an excellent summary of progress during the past year in all aspects of lung cancer, from prevention/detection through molecular therapies and future perspectives. Each section is written by a handful of international experts.
May 5, 2016
This is an outstanding and provocative editorial comment concerning treatment costs of lung cancer based on an article published in the last issue of the European Respiratory Journal. It reveals discrepancies in access to new therapies based on therapeutic targets due to molecular testing and treatment costs.
September 12, 2015
This randomized trial compared induction therapy for pathologically-proven N2/IIIA NSCLC with 3 cycles of cisplatinum and docetaxel chemotherapy alone to chemotherapy combined with 44 Gy of radiation therapy. 232 pts in 23 centers were enrolled over a 12 year period. No differences were identified in the chemotherapy vs chemoradiotherapy groups for